Get started
Author

Snehit Prabhu

Observed names: Prabhu, Snehit, S. Prabhu, Snehit A. Prabhu
Observed institutions: Broad Institute, IBM (India), Stanford Medicine, Stanford Cancer Institute, Columbia University, Stanford University
ORCID: 0000-0001-8589-3087
Observed ORCID: 0000-0001-8589-3087
OpenAlex ID: A5084882436
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
2022 · Robbie G. Majzner, Sneha Ramakrishna, et al. · Nature · 867
PDF
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
2021 · Evan W. Weber, Kevin R. Parker, et al. · Science · 663
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework
2018 · Sean V. Tavtigian, Marc S. Greenblatt, et al. · Genetics in Medicine · 628
PDF
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
2022 · Zinaida Good, Jay Y. Spiegel, et al. · Nature Medicine · 267
PDF
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
2024 · Michelle Monje, Jasia Mahdi, et al. · Nature · 258
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report
2021 · Liora M. Schultz, Christina Baggott, et al. · Journal of Clinical Oncology · 248
Caenorhabditis elegans mutant allele identification by whole-genome sequencing
2008 · Sumeet Sarin, Snehit Prabhu, et al. · Nature Methods · 242
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
2021 · Vanessa A. Fabrizio, Jaap Jan Boelens, et al. · Blood Advances · 127
PDF
Ultrafast genome-wide scan for SNP–SNP interactions in common complex disease
2012 · Snehit Prabhu, Itsik Pe'er · Genome Research · 110
PDF
Determinants of Divergent Adaptation and Dobzhansky-Muller Interaction in Experimental Yeast Populations
2010 · James B. Anderson, Jason Funt, et al. · Current Biology · 102
PDF
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
2021 · Vanessa A. Fabrizio, Christine L. Phillips, et al. · Blood Advances · 81
PDF
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
2022 · Liora M. Schultz, Anne Eaton, et al. · Journal of Clinical Oncology · 78
Overlapping Pools for High Throughput Targeted Resequencing
2009 · Snehit Prabhu, Itsik Pe’er · Genome Research · 78
PDF
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
2022 · Amy Moskop, Lauren Pommert, et al. · Blood Advances · 68
PDF
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
2022 · Heather E. Stefanski, Anne Eaton, et al. · Blood Advances · 51
A research roadmap for next-generation sequencing informatics
2016 · Russ B. Altman, Snehit Prabhu, et al. · Science Translational Medicine · 42
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
2020 · Liora M. Schultz, Christina Baggott, et al. · Blood · 39
Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis (carHLH) Predicts Poor Survival with Real-World Use of Tisagenlecleucel for B-ALL
2022 · Kevin O. McNerney, Stephanie J. Si Lim, et al. · Blood Advances · 37
PDF
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
2024 · Michelle Monje, Jasia Mahdi, et al. · Nature · 17
PDF
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia
2021 · Jenna Rossoff, Christina Baggott, et al. · Blood · 16
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
2023 · Valentin Barsan, Yimei Li, et al. · EClinicalMedicine · 15
PDF
Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
2020 · Jenna Rossoff, Christina Baggott, et al. · Blood · 8
Towards Distributed Dynamic Web Service Composition
2007 · Snehit Prabhu · International Symposium on Autonomous Decentralized Systems · 8
Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells
2022 · Robbie G. Majzner, Jasia Mahdi, et al. · Cancer Research · 7
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
2025 · Swati Naik, Subodh Selukar, et al. · Blood Advances · 3
PDF
Works count: 70
Citation count: 4,100
H-index: 18
I10-index: 21
Year
Topic
Type